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Abstract: We still do not know how the brain and its computations are affected by nerve cell
deaths and their compensatory learning processes, as these develop in neurodegenerative diseases
(ND). Compensatory learning processes are ND symptoms usually observed at a point when the
disease has already affected large parts of the brain. We can register symptoms of ND such as
motor and/or mental disorders (dementias) and even provide symptomatic relief, though the
structural effects of these are in most cases not yet understood. It is very important to obtain
early diagnosis, which can provide several years in which we can monitor and partly compensate
for the disease’s symptoms, with the help of various therapies. In the case of Parkinson’s disease
(PD), in addition to classical neurological tests, measurements of eye movements are diagnostic.
We have performed measurements of latency, amplitude, and duration in reflexive saccades (RS)
of PD patients. We have compared the results of our measurement-based diagnoses with standard
neurological ones. The purpose of our work was to classify how condition attributes predict the
neurologist’s diagnosis. For n = 10 patients, the patient age and parameters based on RS gave a
global accuracy in predictions of neurological symptoms in individual patients of about 80%. Further,
by adding three attributes partly related to patient ‘well-being’ scores, our prediction accuracies
increased to 90%. Our predictive algorithms use rough set theory, which we have compared with
other classifiers such as Naïve Bayes, Decision Trees/Tables, and Random Forests (implemented in
KNIME/WEKA). We have demonstrated that RS are powerful biomarkers for assessment of symptom
progression in PD.
Keywords: neurodegenerative disease; rough set; machine learning; decision rules
1. Introduction
Experienced neurologists use their knowledge together with statistical intuition to study symptom
development in Parkinson’s disease (PD). By applying statistics to large databases, one can find
significant information about the specificities of PD. However, due to the great variety of patients
symptoms and treatments, some results obtained even from the most prominent experts can be
inconsistent. Applying the most popular statistical averaging methods to such inconsistent conclusions
may give confusing results, even leading to statements that specific care regimens do not effectively
influence “average” PD patients. We may face similar problems when explaining factors resulting in
Sensors 2016, 16, 1498; doi:10.3390/s16091498 www.mdpi.com/journal/sensors
Sensors 2016, 16, 1498 2 of 15
longer, better, and more active lives for people with Parkinson’s. Neurologists from different centers
may also differently interpret the meanings of Unified Parkinson’s Disease Rating Scale (UPDRS)
scores, leading to differing therapies. These problems are expressed in the popular statement “No two
people face Parkinson’s in quite the same way”. People diverge substantially in their combinations of
symptoms, rates of progression, and reactions to treatment. As mentioned above, averaging patients’
symptoms as effects of different therapies gives very crude approximations of results. If we want to
improve such investigations, we need to take into account an excessive diversity of patients’ symptoms
and the changeable effects of cares and therapies in distinctive PD cases. Here we follow an earlier
proposal [1] to extend statistical analysis by data mining and machine learning (ML) methods, which
can give a higher meaning to an individual patient’s symptoms and singular PD development. As a
consequence, our methods will suggest a specific treatment adjusted to different individual patients
that may lead in slowing down symptom progression and improvement of quality of life. Proposed
treatments’ improvements will be based on the granularity of the individual patient’s data (as explained
in the Methods section).
Our symptom classification method can be compared with complex object recognition in the
visual system. The latter’s ability to recognize various objects corresponds roughly to the afferent
ascending pathways that classify object parts at simple levels in lower areas, and more complex ones
in higher areas. In many implementations of such systems, the logic is assumed to be based on ‘and’
conjunctions where several components are necessary for a given classification. These hierarchical
classifications are integrated through analysis of whole object (“holistic”) visual properties at all levels
by descending pathway influences [2], and that follow a complementary ‘or’ logic. In our symptom
classification system, we use rough set (RS) theory, an approach related to granular computing in
which a granule contains all attributes (as in ‘and’ logic) and where interactions between granules are
related to ‘or’ logic [2]. These interactions at multiple levels between measurement and knowledge
will be used to differentiate individual symptoms and treatment variability in a way that parallels in
the above models the process of complex object inspection [3,4]. With the use of machine learning
algorithms, we will determine whether sometimes subtle symptom variations are significant enough
to assist in improving individual patients’ treatments.
Diagnostic findings and neurological test interpretations of individual Parkinson’s patients
depend to some extent on neurologists’ experience. In most cases, they estimate values of the
Hoehn, Yahr, and UPDRS scales, not very precisely and in partly subjective ways. In our data
mining-based system, we have used neurologists’ diagnoses as decision attributes and measurements
as condition attributes.
2. Materials and Methods
Our experiments were performed on 10 PD patients who had undergone Deep Brain Stimulation
(DBS) surgery mainly related to their On-Off sensitivity to a medication (L-Dopa). They were qualified
for the surgery and observed postoperatively in the Dept. of Neurology, Medical University of
Warsaw and received surgical DBS in the Institute of Neurology and Psychiatry at University of
Warsaw (WUM) [5]. We obtained horizontal reflexive saccade (RS) measurements in PD patients
during four sessions designed as S1: MedOffDBSOff, S2: MedOffDBSOn, S3: MedOnDBSOff,
S4: MedOnDBSOn. During the first session (S1), the patient was off medication (L-Dopa) and
the DBS stimulator was Off; in the second session (S2), the patient was off medication, but the
stimulator was ON; in the third session (S3), the patient had completed his/her doses of L-Dopa
and the stimulator was Off, and in the fourth session (S4), the patient was on medication with the
stimulator ON. Changes in motor performance, behavioral dysfunction, cognitive impairment, and
functional disability were evaluated in each session according to the UPDRS. The reflexive saccades
(RS) were recorded by a head-mounted saccadometer (Ober Consulting, Poland) that uses an infrared
eye tracking system coupled with a head tracking system (JAZZ-pursuit—Ober Consulting, Poland).
This has a sampling frequency of 1000 Hz, thus yielding high accuracy and precision in eye tracking.
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Thanks to a head-mounted sensor, it is possible to compensate for possible head movements relative
to the monitor.
A patient was sited at a distance of 60–70 cm from the monitor with head supported by a headrest
in order to minimize head motion. We measured fast eye movements in response to a light spot
switched on and off, moving horizontally from the straight eye fixation position (0◦) to 10◦ to the
left or 10◦ to the right after arbitrary times ranging between 0.5–1.5 s. When the patient fixated eyes
on the spot in the middle marker (0◦) the spot then changed color from white to green, indicating
a signal for performance of RS reflexive saccades (RS); or from white to red meaning a signal for
performing antisaccades (AS). Then the central spot was switched off and one of the two peripheral
targets, selected at random with equal probability, was illuminated instead. There was no time lag
between switching off of the central spot and switching on the peripheral target (gap = 0 task). Patients
had to look at the targets and follow them as they moved in the RS task or made opposite direction
saccades in the AS task. After making a saccade to the peripheral target, the target remained on for
0.1 s, after which another trial was initiated.
In each test, the subject had to perform 20 RS and 20 AS in a row in MedOff (medication off),
within two situations: with DBSOff (S1) and DBSOn (S2). In the next step, the patient took medication
and had a break for one-half to one hour, and then the same experiments were performed, with DBSOff
(S3) and DBSOn (S4). In this work, we have analyzed only RS data using the following population
parameters averaged for both eyes: delay mean (±SD) (standard deviation); amplitude mean (±SD);
max velocity mean (±SD); duration mean (±SD).
2.1. Theoretical Basis
The structure of data is an important point of our analysis. Here, we represent them in the form of
an information system or a decision table. We define such an information system [6] as a pair S = (U, A),
where U, A are nonempty finite sets called the universe of objects and the set of attributes, respectively.
If a ∈ A and u ∈ U, the value a (u) is a unique element of V (where V is denoted as the value set).
The indiscernibility relation of any subset B of A or IND(B), is defined [6] as follows:
(x, y) ∈ IND(B) or xI (B) y if and only if a (x) = a (y) for every a ∈ B, where a (x) ∈ V. IND(B)
is an equivalence relation, and [u]B is the equivalence class of u, or a B-elementary granule. The family
of all equivalence classes of IND(B) will be denoted U/I(B) or U/B. The block of the partition U/B
containing u will be denoted by B(u).
We define a lower approximation of symptoms set X ⊆ U in relation to a symptom attribute B
as BX = {u ∈ U : [u]B ⊆ X}, and the upper approximation of X as BX = {u ∈ U : [u]B ∩ X 6= 0}.
In other words, all symptoms are classified into two categories (sets). The lower movement
approximation set X has the property that all symptoms with certain attributes are part of X, and the
upper movement approximation set has property that only some symptoms with attributes in B are
part of X (for more details see [7]). The difference between the uppper and lower approximations of
X is defined as the boundary region of X: BNB (X). If BNB (X) is empty then X is exact (crisp) with
respect to B; otherwise if BNB (X) 6= φ then X is not exact (i.e., is rough) with respect to B. We say that
the B-lower approximation of a given set X is union of all B-granules that are included in X, and the
B-upper approximation of X is of the union of all B-granules that have nonempty intersection with X.
The system S will be called a decision table S = (U, C, D) where C is the condition and D is the
decision attribute [6,7]. In the decision table, the decision attribute D is placed in the last column, and
condition attributes measured by the neurologist, are placed in other columns. On the basis of each
row in the table, rules describing the condition of each patient can be proposed. As the number of
rules is the same as the number of rows, these rules can have many particular conditions. The main
concept of our approach is to describe different symptoms in different patients by using such rules.
However, as there are large inconsistencies between disease progression and symptoms between
individual patients, and effects of similar treatments are not always the same. In order to describe
such differences our rules must have some “flexibility”, or granularity. In other words, one can also
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think about the probability of finding certain symptoms in a certain group of patients. This approach,
called granular computation, should simulate the way in which experienced neurologists might
interact with patients. It is the ability to perceive a patient’s symptoms at various levels of
granularity (i.e., abstraction) in order to abstract and consider only those symptoms that are universally
significant and serve to determine a specific treatment(s). Looking into different levels of granularity
determines the different levels of knowledge abstraction (generality), as well as assisting with
greater understanding of the inherent knowledge structure. Granular computing simulates human
intelligentce related to classification of objects in the sensory system (e.g., vision [2–5]) and motor [1]
system as well as in task-specific problem solving behaviors.
We have also defined the notion of a reduct and template [1] as a basis for the decomposition.
A decomposition tree is defined as a binary tree, whose every internal node is labeled by some template
and external node (leaf) is associated with a set of objects matching all templates in a path from the
root to a given leaf [8].
In our tests, we have divided our data into two or more subsets (mostly to four or six
subgroups—four- or six-folding cross-validation tests). By training on all except one of these
subgroups (the training set) using machine learning (ML), we have obtained classifiers that when
applied to the remaining (test) set gave new numerical decision attributes. In the next step, we have
correlated decision attributes obteined by ML with neurologist decision attributes in order to get a
confusion matrix.
2.2. Computational Basis
We have extended our previous work [1] with new classification methods that were performed
with the help of the KNIME Analytics Platform and WEKA. As a result, we have added new
algorithms including:
• Random Forest (two implementations: KNIME and WEKA) [9]
• Decision Tables (two implementations: KNIME and WEKA) [10]
• Bayes classifier (KNIME implementation) [11]
• Tree ensembles (KNIME implementation)
Tree ensemble models build classifiers based on ensembles of the decision trees that may be seen
as random forest variants. As in the random forest model, training can be done on different sets of
rows (records) and/or columns (describing attributes). The output model describes an ensemble of
decision trees and is implemented by a simple majority vote.
We have applied certain sets of parameters for each of the above-mentioned algorithms. For the
naïve Bayes classifier, we have use 0 as the default probability and 20 as the maximum number of
nominal values per attribute. For the decision tree, we have used the gini index as a quality measure,
no pruning with the reduced error option, a minimum number of records was 2, a maximum number
of records per view was 1000, an average split point and the skipping of nominal columns without
domain information. In the case of the WEKA implementation, we used the following evaluation
metrics: accuracy (for discrete classes) and root mean square error (for numeric classes). For tree
ensembles and the random forest (where applicable), we used the information gain ratio as split
criteria, mid plot split, no tree limit, minimum split size and child node size, square root attribute
sampling for columns, 100 of model number, different attribute set for each tree node. In the case of
WEKA implementation, the number of trees was limited to 10.
Input data for those algorithms were prepared using native KNIME nodes. Processing included
as it was in the original work discretization function. It is important to note that the discretization
function in KNIME is much simpler that the one used in RSES. In comparison, the more sophisticated
RSES discretizes functions, generating cuts based on decision attributes [12]; it bins numerical values
into groups with equal frequencies.
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In addition to the standard accuracy coefficient, we have also calculated from the confusion
matrix the Matthews correlation coefficient that is a correlation coefficient between the observed and
predicted binary classifications. We also have used SMOTE in order to oversample our data, and we
have used nearest neighbor 3 with oversample by three parameters.
2.3. Dedicated Database
In the course of this study, a dedicated database for patients and measurement data has been
designed and implemented. Given the number of patients under consideration and a moderate volume
of the processed data, this project did not pose significant data management challenges. However,
both the immediate needs of data analysis, and plans for the future maintenance of the dataset and
the development of the related data collection and retrieval functionality, brought some important
architectural and functional requirements.
To help protect the data integrity, both the alphanumerical data as well as the associated files (in the
form of Binary Data Objects) are kept under the control of the database management system. The core
structure of the database is designed to match the exact needs of the current research. It consists of
the anonymized patient data, their associated history of examinations, and finally their measurement
variants—with respect to the DBS (deep brain stimulation) and BMT (medication) on/off configuration.
Given the number of the attributes and the evolution of their set in the early phase of the project,
it became necessary to redesign the data structure to allow a greater degree of generality. Hence the
structure is open for further extensions in terms of:
• Defining new attributes describing the Patient, Examination, and Measurement entities;
• Defining associated constraints or the dictionary of enumerative values for those attributes;
• Defining new types of files for storing additional information regarding Patients, Examinations,
and Measurements;
• Establishing a numbering and naming convention for the instances of the above mentioned
entities and files.
Although the current setup involves only the data collection and interface by a single
team, the software is being prepared for functioning in a more distributed and versatile manner.
The functionality under development includes:
• Web service interfaces for contributing measurements made with mobile devices;
• Advanced privilege management functionality to allow multiple-team collaboration and support
for different access levels;
• Internationalization in terms of user interface language and data and metadata language;
• Integration with the human motion database, to extend the scope of future examination.
The database is currently operated by PJAIT and is to be maintained after the completion of the
current project.
3. Results
3.1. Neurological Tests and Eye Movement Measurements
The mean age of the patients was 51.1 ± 10.2 (SD) years, mean disease duration was
11.3 ± 3.2 years, mean UPDRS (related to all symptoms) were: S1: 66.6 ± 13.8; S2: 30.0 ± 16.3;
S3: 58.1± 13.5; S4: 22.3 ± 13.6; mean UPDRS III (related only to motor symptoms): S1: 42.7 ± 11.3;
S2: 17.8± 10.6; S3: 34.1± 10.8; S4: 10.9± 8.3; mean RS latencies: S1: 291.2± 93.1 ms, S2: 199.6± 39.5 ms,
S3: 232.9 ± 82.7 ms; S4: 183.2 ± 30 ms.
Differences between latencies: S1-S2, and S1-S4 were statistically significant (t-test p < 0.01) even
when they were variable in individual patients (Figure 1); meanwhile S1-S3 was not statistically
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significant; this is similar to differences between UPDRS/UPDRS III: S1-S2 and S1-S4 were statistically
significant (p < 0.001), and S1-S3 was not statistically significant.Sensors 2016, 16, 1498 6 of 16 
 
 
Figure 1. An example of experimental recordings from Pat #38 in two sessions: upper plots from 
session S1: MedOFF & StimOFF; lower plots from session S4: MedON & StimON; left plots show 
latency measurements, right plots—saccade amplitude and velocity. Notice change in variability of 
responses between S1 and S4. These plots were obtained directly from the saccadometer (Ober 
Consulting), different colours are related to different eyes. 
Other parameters of RS did not change significantly with the session number. 
3.2. Rough Set and Machine Learning Approach 
As described above, we have used the RSES 2.2 (Rough System Exploration Program) [8] in order 
to find regularities in our data. At first, our data were placed in an information table (Table 1) as 
originally proposed by Pawlak [6]. 
Table 1. Extract from the information table. 
P# age sex t_dur S# UPDRS HYsc SccDur SccLat SccAmp SccVel
28 54 1 8 1 58 2.0 43 402 12 566.9 
28 54 1 8 2 40 1.0 46 297 11 474.5 
28 54 1 8 2 40 1.0 49 227 10 431.2 
28 54 1 8 4 16 1.0 47 198 9 376.2 
38 56 0 11 1 49 2.5 42 285 14 675.2 
38 56 0 11 2 22 1.5 48 217 12 509.7 
38 56 0 11 3 37 2.5 43 380 14 638.9 
38 56 0 11 4 12 1.5 45 187 10 482.6 
The full table has 15 attributes and 36 objects (measurements). In Table 1 are values of 11 
attributes for two patients: P#—patient number, age—patient’s age, sex—patient’s sex: 0—female, 
1—male, t_dur—duration of the disease, S#—Session number, UPDRS—total UPDRS, HYsc—Hoehn 
and Yahr scale all measured by the neurologist and saccades measurements: SccDur—saccade 
duration; SccLat—sac-cade latency; SccAmp—saccade amplitude, and SccVel—saccade velocity. 
In the next step, we have performed reduction of attributes (see reduct in the Methods section) 
to a minimum number of attributes describing our results. We have also created a discretization table: 
. n example of experimental recordings from Pat #38 in two sessions: upper plots from ession
S1: MedOFF & StimOFF; lower p ts from session S4: MedON & StimON; left plots show latency
measure ents, right plots—saccade amplitude and velocity. Noti e change in variability of responses
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Other parameters of RS did not change significantly with the session number.
. ( t l
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P# Age Sex t_dur S# UPDRS HYsc SccDur SccLat SccAmp SccVel
28 54 1 8 1 58 2.0 43 402 12 566.9
28 54 1 8 2 40 1.0 46 297 11 474.5
28 54 1 8 2 40 1.0 49 27 10 431.2
28 54 1 8 4 16 1.0 47 198 9 376.2
38 56 0 11 1 49 2.5 42 285 14 675.2
38 56 0 11 2 22 1.5 48 217 12 509.7
38 56 0 11 3 37 2.5 43 380 14 638.9
38 56 0 11 4 12 1.5 45 187 10 482.6
The full table has 15 attributes and 36 objects (measurements). In Table 1 are values of 11 attributes
for two patients: P#—patient number, age—patient’s age, sex—patient’s sex: 0—female, 1—male,
t_dur—duration of the disease, S#—Session number, UPDRS—total UPDRS, HYsc—Hoehn and
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Yahr scale all measured by the neurologist and saccades measurements: SccDur—saccade duration;
SccLat—sac-cade latency; SccAmp—saccade amplitude, and SccVel—saccade velocity.
In the next step, we have performed reduction of attributes (see reduct in the Methods section) to
a minimum number of attributes describing our results. We have also created a discretization table:
here, single values of measurements were replaced by their range (as describe in the Method section
on cut sets). As the result we have obtained the decision table (Table 2—see below).
Table 2. Part of the decision discretized-table.
P# Age t_dur S# HYsc SccDur SccLat SccAmp UPDRS
28 (−Inf, 55.0) * 1 * (−Inf, 45.5) (260.0, Inf) (10.5, Inf) (55.0, Inf)
28 (−Inf, 55.0) * 2 * (45.5, Inf) (260.0, Inf) (10.5, Inf) (22.5, 55.0)
28 (−Inf, 55.0) * 2 * (45.5, Inf) (−Inf, 260.0) (−Inf, 10.5) (22.5, 55.0)
28 (−Inf, 55.0) * 4 * (45.5, Inf) (−Inf, 260.0) (−Inf, 10.5) (14.0, 22.5)
38 (55.0, Inf) * 1 * (−Inf, 45.5) (260.0, Inf) (10.5, Inf) (22.5, 55.0)
38 (55.0, Inf) * 2 * (45.5, Inf) (−Inf, 260.0) (10.5, Inf) (14.0, 22.5)
38 (55.0, Inf) * 3 * (−Inf, 45.5) (260.0, Inf) (10.5, Inf) (22.5, 55.0)
38 (55.0, Inf) * 4 * (−Inf, 45.5) (−Inf, 260.0) (−Inf, 10.5) (−Inf, 14.0)
In the first column is the patient number, in the second the patient age, dividing our group into
patients below (Pat#28) or above (Pat#38) 55 years of age; disease duration and the Hoehn and Yahr
scale were not considered important (stars), along with session number. Other parameters of saccades
were also divided into ranges. It is interesting to note how the UPDRS were divided into different
ranges: above 55, 22.5 to 55, 14 to 22.5, and below 14 (the last column). On the basis of this decision
table, we can write the following rule:
(‘Pat’ = 38) & (‘age’ = “(55.0, Inf)”) & (‘Sess’ = 4) & (‘SccDur’ = “(−Inf, 45.5)”) &
(‘SccLat′ = “(−Inf, 260.0)′′)& (‘SccAmp′) = “(−Inf , 10.5)′′) => (‘UPDRS′ = “(−Inf, 14.0)′′) (1)
We read this formula above (Equation (1)), as stating that each row of the table (Table 2) can be
written in form of such equation. It states that if we evaluate patient #38 and with age above 55 years
and in session #4 and with saccade duration below 45.5 ms and saccade latency below 260 ms and . . .
and saccade amplitude below 10.5, then the patient’s UPDRS is below 14.
3.2.1. Estimation of UPDRS on the Basis of Eye Movement Measurements
In the next step, we need to find common rules for these equations by using a data mining system
based on rough set theory [6]. We have tested our rule using machine-learning (ML) algorithms.
At first, we have randomly divided our data into six groups (so-called a six-fold cross-validation
method). We took five groups as a training set and tested the sixth one. By changing groups belonging
to the training and test sets, we have removed the effect of accidental group divisions. The results of
each test were averaged. The results are given as a confusion matrix (Table 3). In this case, as a ML
algorithm that gave the best results we have used the decomposition tree (see the Methods section).
Table 3. Confusion matrix for UPDRS Total binned into four classes. Column headers represent
predicted values and row headers represent actual values.
55.0, Inf 22.5, 55.0 −Inf, 14.0 14.0, 22.51 ACC
55.0, Inf 0.3 0.3 0.0 0.0 0.2
22.5, 55.0 0.0 1.5 0.0 0.0 1.0
−Inf, 14.0 0.0 0.3 0.0 0.2 0.0
14.0, 22.5 0.0 0.0 0.0 0.0 0.0
TPR 0.2 0.8 0.0 0.0
TPR: True positive rates for decision classes, ACC: Accuracy for decision classes: the global coverage was 0.44,
the global accuracy was 0.79, coverage for decision classes: 0.2, 0.5, 0.3, 0.0.
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3.2.2. Estimation of UPDRS on the Basis of Eye Movement and Additional Measurements
Next, we extended our tests (in comparison with [1]) by adding to our dataset additional
attributes, including:
• PDQ39—quality of life measure
• AIMS—Abnormal Involuntary Movement Score
• Epworth—sleep scale
A significant increase in accuracy was achieved in prediction of Total UPDRS by adding the PDQ
attribute. We were able to achieve 90.3% of accuracy with 47% coverage. We can see confusion matrix
for this classification in Table 4.
Table 4. Confusion matrix for total UPDRS prediction with PDQ, AIMS, and Epworth attributes.
Column headers represent predicted values, and row headers represent actual values.
“(55, 94]” “(25, 40]” “[6, 25]” “(40, 55]” ACC
“(55, 94]” 0.5 0.17 0 0 0.417
“(25, 40]” 0 0.5 0 0 0.5
“[6, 25]” 0 0 1.17 0 1
“(40, 55]” 0 0 0.17 0.33 0.333
TPR 0.5 0.42 0.94 0.33
We have performed several tests trying to predict UPDRS values on the basis of measured saccade
properties. As changes in UPDRS and saccade latencies were similar when the session number was
changed (Figure 2) we tried to predict individual UPDRS values only from RS latencies. When the
session number, patient age, RS latency, amplitude, and duration were added, the global accuracy in
UPRDS prediction was about 80% (ML: decomposition tree, cross-validation-method). As UPDRS is
a standard measurement in PD, the above results give the possibility of at least partly replacing or
augmenting neurologist estimates with the eye movements (EM) measurement results.
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Figure 2. This graph shows parallel changes in UPDRS and reflexive saccade latencies as functions of 
medication and stimulation. Changes between control and MedOnStimOn were significantly 
different for UPDRS p < 0.001, RS p < 0.01. 
3.2.3. Estimation of Different Therapies Effects 
Another question that arises is whether EM can help to estimate possible effects of different 
treatments in individual patients. In order to demonstrate an answer, we have removed EM 
measurements and added other typically measured attributes such as: Schwab and England ADL 
Scale, and UPDRS III and UPDRS IV to the decision table and tried to predict the effects of different 
treatments as represented by sessions 1 to 4 (medication and stimulation effects). Table 5 is a part of 
full decision discretized-table with decision attributes—the session number placed in the last column. 
On the basis of this table, we have formulated rules using a rough set system and tested them with 
randomly divided data into six groups. We took five as a training set (using ML protocol) and tested 
Figure 2. This graph shows parallel changes in UPDRS and reflexive saccade latencies as functions of
medication and stimulation. Changes between control and MedOnStimOn were significantly different
for UPDRS p < 0.001, RS p < 0.01.
3.2.3. Estimation of Different Therapies Effects
Another question that arises is whether EM can help to estimate possible effects of different
treatments in individual patients. In order to demonstrate an answer, we have removed EM
measurements and added other typically measured attributes such as: Schwab and England ADL
Scale, and UPDRS III and UPDRS IV to the decision table and tried to predict the effects of different
treatments as represented by sessions 1 to 4 (medication and stimulation effects). Table 5 is a part of
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full decision discretized-table with decision attributes—the session number placed in the last column.
On the basis of this table, we have formulated rules using a rough set system and tested them with
randomly divided data into six groups. We took five as a training set (using ML protocol) and tested
with sixth. In order to remove effect of the accidental division, we have exchanged training and test
groups and averaged results placed in the confusion matrix (Table 6).
Table 5. Part of the decision discretized-table without eye movement measurements.
Pat# Age t_dur SEngs UPDRS III UPDRS IV UPDRS Sess#
(27.5, 41.5) (43.5, Inf) * (−Inf, 75) (36.0, 46.0) (10.5, Inf) (1.75, Inf) 1
(27.5, 41.5) (43.5, Inf) * (75, Inf) (13.0, 26.0) (10.5, Inf) (−Inf, 1.75) 2
(27.5, 41.5) (43.5, Inf) * (75, Inf) (−Inf, 6.0) (10.5, Inf) (−Inf, 1.75) 4
(27.5, 41.5) (43.5, Inf) * (−Inf, 75) (26.0, 36.0) (10.5, Inf) (1.75, Inf) 1
(27.5, 41.5) (43.5, Inf) * (75, Inf) (13.0, 26.0) (10.5, Inf) (−Inf, 1.75) 2
(27.5, 41.5) (43.5, Inf) * (−Inf, 75) (13.0, 26.0) (10.5, Inf) (1.75, Inf) 3
(27.5, 41.5) (43.5, Inf) * (75, Inf) (−Inf, 6.0) (10.5, Inf) (−Inf, 1.75) 4
Where * (star) is related to parameter(s) excluded (not significant) in the discretization process.
Table 6. Confusion matrix for different session numbers (S1–S4). Column headers represent predicted
values and row headers represent actual values.
1 2 3 4 ACC
1 0.5 0.0 0.5 0.0 0.3
2 0.0 0.5 0.0 0.3 0.4
3 0.8 0.0 0.2 0.0 0.2
4 0.0 0.5 0.0 0.5 0.4
TPR 0.3 0.3 0.2 0.4
TPR: True positive rates for decision classes, ACC: Accuracy for decision classes: the global
coverage was 0.64, the global accuracy was 0.53, coverage for decision classes: 0.5, 0.5, 0.75, 0.7.
We have performed the same procedures once more (results of discretization are in Table 7) in
order to test results of patients’ eye movement influence on our predictions (presented as a confusion
matrix in Table 8).
Table 7. Part of the decision discretized-table with eye movement measurements.
Pat# Age SccVel UPDRS III HYsc SccDur SccLat SccAmp Ses#
(27.5, 34.5) * (458.5, 578.0) (36, Inf) (1.75, Inf) (38, Inf) (308.5, Inf) * 1
(27.5, 34.5) * (458.5, 578) (11.5, 36) (−Inf, 1.75) (38.0, Inf) (−Inf, 308.5) * 2
(27.5, 34.5) * (341.5, 403) (−Inf, 11.5) (−Inf, 1.75) (38, Inf) (−Inf, 308.5) * 4
(34.5, Inf) * (665.5, Inf) (11.5, 36.0) (1.75, Inf) (38.0, Inf) (−Inf, 308.5) * 1
(34.5, Inf) * (458.5, 578) (11.5, 36) (−Inf, 1.75) (38.0, Inf) (−Inf, 308.5) * 2
(34.5, Inf) * (578.0, 665.5) (11.5, 36) (1.75, Inf) (38.0, Inf) (308.5, Inf) * 3
(34.5, Inf) * (458.5, 578) (−Inf, 11.1) (−Inf, 1.75) (38, Inf) (−Inf, 308.5) * 4
Table 8. Confusion matrix for different session numbers (S1–S4). Column headers represent predicted
values and row headers represent actual values.
1 2 3 4 ACC
1 0.8 0.0 0.0 0.0 0.7
2 0.0 0.7 0.0 0.0 0.7
3 0.2 0.0 0.8 0.0 0.6
4 0.0 0.2 0.0 0.3 0.25
TPR 0.7 0.7 0.6 0.25
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TPR: True positive rates for decision classes, ACC: Accuracy for decision classes, the global
coverage was 0.5; the global accuracy was 0.91; coverage for decision classes: 0.6, 0.6, 0.6, 0.25.
As above, results of each test were averaged in a six-fold cross-validation resulting a confusion
matrix (Table 8). As a machine-learning algorithm, we have used the decomposition tree (see Methods).
In the next step, we have extended our data set by three additional parameters: PDQ39, AIMS, Epworth
and performed discretization as is shown below in Table 9.
Table 9. Part of the discretized decision table for session prediction. As we can see for this dataset only
PDQ scale give significant value for prediction results.
Pat# UPDRS_III SEsc SccLat SccDur SccAmp PDQ39 Ses#
25 (36.0, 44.5) (−Inf, 85.0) (207.64, Inf) (42.5, Inf) (9.9, Inf) (−Inf, 78.5) 1
63 (13.0, 26.0) (85.0, Inf) (207.64, Inf) (42.5, Inf) (−Inf, 9.9) (78.5, Inf) 4
25 (36.0, 44.5) (−Inf, 85.0) MISSING MISSING MISSING (−Inf, 78.5) 3
25 (−Inf, 6.0) (85.0, Inf) (207.64, Inf) (42.5, Inf) (9.9, Inf) (−Inf, 78.5) 4
63 (26.0, 36.0) (−Inf, 85.0) (207.64, Inf) (−Inf, 42.5) (9.9, Inf) (78.5, Inf) 1
all the rest (36.0, 44.5) (85.0, Inf) (207.64, Inf) (42.5, Inf) (9.9, Inf) (−Inf, 78.5) 2
all the rest (44.5, Inf) (−Inf, 85.0) (207.64, Inf) (−Inf, 42.5) (−Inf, 9.9) (−Inf, 78.5) 3
By extending our dataset with additional attributes we were able to achieve 4% more in accuracy
for session prediction that make it 94.4% level. The confusion matrix for this test can be found in
Table 10.
Table 10. Table below shows the confusion matrix for extension of our previous results in prediction
session. Global accuracy was established on 94.4% with 47% coverage. We used six-fold cross validation
method with tree decomposition algorithm. Column headers represent predicted values, row headers
represent actual values.
1 2 3 4 ACC
1 0.5 0 0 0 0.333
2 0 0.83 0 0 0.5
3 0 0 0.33 0 0.333
4 0 0.17 0 1 0.75
TPR 0.33 0.42 0.33 0.83
3.2.4. Estimation of UPDRS II and UPDRS III on the Basis of Eye Movement and
Additional Measurements
Further on, we have extended our original work [1] by creating models for predicting other
attributes; the best results we were able to achieve for UPDRS II and III, reaching 85% accuracy and
67.7% coverage for UPDRS II, and 81.7% accuracy and 61.1% coverage for III. Below we can see detailed
discretized tables used in those models (Table 11 for UPDRS III) as well as confusion matrixes (Table 12
for UPDRS III, Table 13 for UPDRS II).
Table 11. Fragment of decision table for UPDRS III model.
Pat# UPDRS II Ses# SccLat PDQ39 UPDRS III
{11, 14, 25, 27, 28, 41, 45, 64} (14.5, Inf) {‘S2’} (259.695, Inf) (65.5, Inf) (14, 24]
{11, 14, 25, 27, 28, 41, 45, 64} (−Inf, 14.5) {‘S3’} (−Inf, 259.695) (65.5, Inf) (24, 35]
{11, 14, 25, 27, 28, 41, 45, 64} (−Inf, 14.5) * (−Inf, 259.695) (65.5, Inf) [2, 14]
38 (14.5, Inf) {‘S1’} (259.695, Inf) (−Inf, 65.5) (24, 35]
38 (−Inf, 14.5) {‘S2’} (−Inf, 259.695) (−Inf, 65.5) (14, 24]
38 (14.5, Inf) {‘S3’} (259.695, Inf) (−Inf, 65.5) (14, 24]
63 (14.5, Inf) {‘S1’} (−Inf, 259.695) (65.5, Inf) (24, 35]
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Table 12. Confusion matrix for UPDRS III model. Classification accuracy 81.7%, 61.1% coverage,
40 examination records. Test method: six-fold cross validation.
“(35, 63]” “(14, 24]” “(24, 35]” “[2, 14]” ACC
“(35, 63]” 1.33 0 0.33 0 0.667
“(14, 24]” 0 0 0 0.17 0
“(24, 35]” 0 0 0.67 0 0.667
“[2, 14]” 0 0.33 0 0.83 0.417
TPR 0.83 0 0.58 0.5
Table 13. Confusion matrix for UPDRS II classifier. Accuracy 78.6%, coverage 75.7%. 40 examination
records classified with decomposition tree and six-fold cross validation method.
“(19, 25]” “[1, 10]” “(13, 19]” “(10, 13]” ACC
“(19, 25]” 1.33 0 0 0 0.833
“[1, 10]” 0 0.83 0 0.33 0.5
“(13, 19]” 0 0 1 0 0.5
“(10, 13]” 0 0.5 0.33 0.17 0.056
TPR 0.83 0.58 0.5 0.08
When we have compared above results for predicting accuracy for UPDRS II to predictions
without PDQ, AIMS, and Epworth attributes, and we have noticed decreased accuracy in predictions
from 78.7% to 62.2% (16.4% difference).
3.3. Comparison of Rough Set Based and Other Classifiers
Our ultimate purpose was to compare our models built using RS methods with other well-known
algorithms. To accomplish this, we have used the same information tables and processed them with
different classification algorithms as described in the methods section and results are shown below in
Table 14.
Table 14. As we can for those data sets we were able to achieve the most accurate results for the
Rough Set-based approach but in most cases there were algorithms that could give predictions on a
similar level, with the exception of classifiers for the session. Classifiers were tested on dataset with
PDQ attribute.
Classifier UPDRS Total UPDRS II UPDRS III Sess#
Bayes 53.17% 77.38% 32.54% 0.00%
Decision Tree 50.79% 7.94% 62.30% 30.16%
Random Forest 67.86% 79.76% 60.32% 25.00%
Tree Ensemble 65.48% 70.24% 54.76% 25.00%
WEKA-Random Forest 47.62% 73.02% 49.60% 12.30%
WEKA-Decision Table 62.54% 43.25% 77.38% 35.71%
Rough Set 90.30% 78.60% 81.70% 94.40%
In summary, our new results have demonstrated that adding eye movement (EM) measurements
to classical neurological data performed as the ‘gold standard’ by the most clinicians, improved
predictions of disease progression, as measured by improvement in global accuracy from 0.53 to 0.91.
The EM measurements may also partly replace some standard neurological measurements such as
the UPDRS, as global accuracy of the total UPDRS predictions taken from EM data was 0.79 for our
10 PD patients. We have also performed comparisons to other well-known ML algorithms showing
competitiveness of the RS algorithm (Table 14). All data from this study are shown in Table A1
(Appendix A). We have also tested influence of different training and testing sets on the accuracy
of our classifications (Table B1, Table C1 in Appendixs B and C). We have used four-, five-, six-fold,
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and leave-one-out (40-fold for our dataset) tests. In the majority of tests for different classifiers
(Table B1 in Appendix B), the six-fold gave similar accuracy to four- or five-fold and leave-one-out tests.
However, for the rough set based classification in the majority of different parameters tests six-fold
trials were the best.
As our database is relatively small, we did not perform direct subsampling only oversampling by
3 with help of SMOTE. It was surprising that oversampling gave the best results for all algorithms.
It is probably related to the fact that our dataset is small, as our inter-rater quantitative agreement
measured by the Cohen’s kappa was substantial (0.7) for all test with WEKA-Decision Table.
We have also calculated the Matthews correlation coefficient (MCC) as another measure of
prediction accuracy, which can be interpreted as a correlation coefficient between the observed and
predicted classifications (Tables B1 and C1). We have got significant MCC with rough set based
classification for UPDRS and session number (0.85 and 0.95—Table C1 in Appendix C), but for other
algorithms only for the oversampled data (Table B1 in Appendix B).
4. Discussion
As mentioned above, there are significant differences between symptom developments and
effects of different treatments in individual PD patients. As a consequence, even with large
numbers of approaches and clinical trials, there still have been few conclusive results on direct
therapeutic connection to quantitative changes in PD symptoms. There are numerous reasons for
such disappointments: first, the limitations of current disease models in target validation and testing;
second, difficulties in choosing clinical endpoints; third, problems in finding sensitive biomarkers
of disease progression. The major drawback is that disease starts long before an individual patient
notices the first disturbing motor symptoms. As mentioned above, a consequence of brain plasticity is
compensation for loss of neurons, to an extent that subjects do not realize that problems are occurring
in their brains over one or two decades at a time. Another aspect is that, because individual brains
develop different specific compensatory mechanisms, individual pathologies form a large spectrum.
Therefore, one needs new, more sensitive, possibly automatic and intelligent methods that may help in
early diagnosis. In this study, we have given an example comparing classical neurological diagnostic
protocols with a new approach. The main difference between these types of measures is in their
precision and objectivity. Our approach is doctor-independent, and can be performed automatically
and more often than standard doctor’s visits. In the near future, it may help in transforming some
hospital-based to home-based treatments. In this scenario, it will be possible to measure patient
symptoms at home, and send these for consultation by neurologists. Such methods will be faster, more
precise, and can help with more frequent measurements. As a consequence, they may help not only to
determine more objectively a patient’s symptoms, but also to follow up disease progression in more
frequent intervals, something not possible currently, with the limited time resources of neurologists.
If we obtain such information, it may lead to more appropriate therapies and slowing down of disease
progression. It is one of the purposes of this work to try to extract knowledge from symptoms in order
to further develop more appropriate therapies and better control disease development.
5. Conclusions
We have presented a comparison of classical statistical averaging methods related to doctors’
intuition and their PD diagnosis with different AI approaches. We have used processed neurological
data from PD patients in four different treatments and have plotted averaged effects of medication
and brain stimulation in individual patients. As these effects are strongly patient-dependent, they
could not give enough information to predict new patients’ behavior. The AI approaches (such as
machine learning and data mining) are more universal, giving general rules for predicting individual
patient responses to treatments as demonstrated above (in UPDRS, UPDRS II, UPDRS III, or session
number predictions).
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11 1955 25 45 3 75 4 60 259.1 51.9 14.5 552.2 43 2 8 1
11 1955 10 17 3 32 1 90 204.4 51.6 14.3 549.7 43 2 8 2
11 1955 25 32 3 62 4 60 314.6 46.2 12.2 514 43 2 8 3
11 1955 10 10 3 25 1 90 238.8 54.4 10.8 371.7 43 2 8 4
14 1979 17 43 0 61 3 60 173 52 9.19 393 31 0 8 1
14 1979 8 14 0 23 1.5 90 184 51 10.9 464 31 0 8 2
14 1979 17 32 0 50 3 60 331 45 9.1 506 31 0 8 3
14 1979 8 9 0 18 1.5 90 172 48 10.5 462 31 0 8 4
25 1956 20 40 2 62 3 70 301.8 49.1 10 386.1 29 0 10 1
25 1956 3 2 2 7 1 100 29 0 10 2
25 1956 20 40 2 62 3 70 29 0 10 3
25 1956 3 2 2 7 1 100 243.3 47.2 14.7 607.6 29 0 10 4
27 1954 25 63 4 94 4 60 474.7 43.3 10.1 475 78 4 12 1
27 1954 13 37 4 56 1.5 90 260.5 44.9 10.7 485 78 4 12 2
27 1954 25 53 4 84 4 60 411.2 32.7 8.5 559.6 78 4 12 3
27 1954 13 24 4 43 1.5 90 217.8 45.9 9.5 446.4 78 4 12 4
28 1959 17 40 0 58 2 60 401.7 43.2 12.2 566.9 68 0 12 1
28 1959 18 21 0 40 1 90 296.6 45.8 11.3 474.5 68 0 12 2
28 1959 11 27 7 46 1.5 80 227.1 48.6 10.4 431.2 68 0 12 3
28 1959 11 4 0 16 1 100 198.3 46.8 9 376.2 68 0 12 4
38 1957 19 28 2 49 2.5 70 285.1 42.2 14.2 675.2 63 3 5 1
38 1957 5 15 2 22 1.5 90 216.7 47.6 11.6 509.7 63 3 5 2
38 1957 19 16 2 37 2.5 70 380.4 42.8 14.4 638.9 63 3 5 3
38 1957 5 5 2 12 1.5 90 187.3 44.5 10 482.6 63 3 5 4
41 1980 18 37 0 55 2 80 267.7 41.9 8.8 383.7 23 0 7 1
41 1980 1 7 0 8 1 100 183.5 47.3 8.4 311.7 23 0 7 2
41 1980 18 35 0 53 2 80 244.4 43.3 14.4 656.7 23 0 7 3
41 1980 1 5 0 6 1 100 182 51 10.6 377.2 23 0 7 4
45 1944 15 42 0 62 3 60 255 44 8.8 396 63 0 7 1
45 1944 13 21 0 39 1.5 90 336 44 10.3 459 63 0 7 2
45 1944 15 27 0 47 3 60 331 43 9.3 406 63 0 7 3
45 1944 13 12 0 30 1.5 90 241 46 10.7 458 63 0 7 4
63 1960 23 26 2 54 3 70 227.6 42.3 15.8 701.5 89 0 12 1
63 1960 13 18 2 36 1.5 90 207.4 41.8 13.4 626.79 89 0 12 2
63 1960 23 26 2 54 3 70 187.7 44.3 14.2 604.79 89 0 12 3
63 1960 13 16 2 34 1.5 90 258.89 42.9 8.19 357.7 89 0 12 4
64 1957 24 49 2 77 4 60 230.3 46.6 7.7 382.7 104 15 1
64 1957 29 2 33 2 80 104 15 2
64 1957 39 2 43 4 60 104 15 3
64 1957 12 23 2 39 2 80 194.1 43.2 7.2 326.89 104 15 4
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Appendix B
Table B1. Comparison of different classifiers with accuracy (ACC) and Matthews correlation coefficient
(MCC) for different classifiers.
Fold# Alglorithm ACC MCC
4 fold Bayes 0.425 0.25730532
4 fold Decision Tree 0.45 0.26164055
4 fold Random Forest 0.625 0.50898705
4 fold Tree Ensemble 0.65 0.53175848
4 fold WEKA-Decision Table 0.775 0.70116894
4 fold WEKA-Random Forest 0.45 0.27670875
40 fold Bayes 0.525 0.38539238
40 fold Decision Tree 0.62162 0.49525773
40 fold Random Forest 0.675 0.56408389
40 fold Tree Ensemble 0.725 0.63448742
40 fold WEKA-Decision Table 0.775 0.7007412
40 fold WEKA-Random Forest 0.55 0.38935439
5 fold Bayes 0.525 0.36809666
5 fold Decision Tree 0.41026 0.21908988
5 fold Random Forest 0.6 0.46007798
5 fold Tree Ensemble 0.7 0.60544001
5 fold WEKA-Decision Table 0.775 0.69943346
5 fold WEKA-Random Forest 0.6 0.46723502
6 fold Bayes 0.53 0.33183479
6 fold Decision Tree 0.51 0.17393888
6 fold Random Forest 0.68 0.55837477
6 fold Tree Ensemble 0.65 0.49267634
6 fold WEKA-Decision Table 0.48 0.7007412
6 fold WEKA-Random Forest 0.63 0.49387519
6 fold/SMOTE Bayes 0.95 0.9339666
6 fold/SMOTE Decision Tree 0.93082 0.90779989
6 fold/SMOTE Random Forest 0.975 0.96619735
6 fold/SMOTE Tree Ensemble 0.975 0.96675826
6 fold/SMOTE WEKA-Decision Table 0.9125 0.88469729
6 fold/SMOTE WEKA-Random Forest 0.95625 0.94205299
Appendix C
Table C1. Comparison rough set classifiers with different fold number, accuracy (ACC), Matthews
correlation coefficient (MCC).
Fold# Dataset Decision Class Algorithm ACC MCC
6 fold no RS session decomposition tree 0.53 0.347106
5 fold no RS session decomposition tree 0.257 0.138529
4 fold no RS session decomposition tree 0.156 0.036866
40 fold no RS session decision rules 0.25 0.017689
6 fold RS + PDQ session decomposition tree 0.944 0.951147
5 fold RS + PDQ session decomposition tree 0.777 0.745525
4 fold RS + PDQ session decomposition tree 0.783 0.789729
40 fold RS + PDQ session decision rules 0.5 0.323653
6 fold RS + PDQ total UPDRS decomposition tree 0.903 0.854696
5 fold RS + PDQ total UPDRS decomposition tree 0.627 0.434957
4 fold RS + PDQ total UPDRS decomposition tree 0.818 0.780431
40 fold RS + PDQ total UPDRS decision rules 0.675 0.549481
6 fold RS + PDQ UPDRS II decomposition tree 0.62 0.244933
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Table C1. Cont.
Fold# Dataset Decision Class Algorithm ACC MCC
5 fold RS + PDQ UPDRS II decomposition tree 0.83 0.736768
4 fold RS + PDQ UPDRS II decomposition tree 0.83 0.699704
40 fold RS + PDQ UPDRS II decision rules 0.7 0.661798
6 fold RS + PDQ UPDRS III decomposition tree 0.817 0.583869
5 fold RS + PDQ UPDRS III decomposition tree 0.543 0.432082
4 fold RS + PDQ UPDRS III decomposition tree 0.506 0.33002
40 fold RS + PDQ UPDRS III decision rules 0.65 0.507846
6 fold with RS session decomposition tree 0.91 0.84503
5 fold with RS session decomposition tree 0.85 0.83524
4 fold with RS session decomposition tree 0.838 0.724788
40 fold with RS session decision rules 0.5 0.323653
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